These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 21958854)
1. Comparing the intracellular fate of components within a noncovalent streptavidin nanoparticle with covalent conjugation. Liu Y; Cheng D; Liu X; Liu G; Dou S; Xiao N; Chen L; Rusckowski M; Hnatowich DJ Nucl Med Biol; 2012 Jan; 39(1):101-7. PubMed ID: 21958854 [TBL] [Abstract][Full Text] [Related]
2. Auger radiation-induced, antisense-mediated cytotoxicity of tumor cells using a 3-component streptavidin-delivery nanoparticle with 111In. Liu X; Wang Y; Nakamura K; Kawauchi S; Akalin A; Cheng D; Chen L; Rusckowski M; Hnatowich DJ J Nucl Med; 2009 Apr; 50(4):582-90. PubMed ID: 19289423 [TBL] [Abstract][Full Text] [Related]
3. Auger-mediated cytotoxicity of cancer cells in culture by an 125I-antisense oligomer delivered as a three-component streptavidin nanoparticle. Liu X; Nakamura K; Wang Y; Cheng D; Liang M; Xiao N; Chen L; Rusckowski M; Hnatowich DJ J Biomed Nanotechnol; 2010 Apr; 6(2):153-7. PubMed ID: 20738069 [TBL] [Abstract][Full Text] [Related]
4. Cell studies of a three-component antisense MORF/tat/Herceptin nanoparticle designed for improved tumor delivery. Liu X; Wang Y; Nakamura K; Kubo A; Hnatowich DJ Cancer Gene Ther; 2008 Feb; 15(2):126-32. PubMed ID: 18084241 [TBL] [Abstract][Full Text] [Related]
5. Simplified preparation via streptavidin of antisense oligomers/carriers nanoparticles showing improved cellular delivery in culture. Wang Y; Nakamura K; Liu X; Kitamura N; Kubo A; Hnatowich DJ Bioconjug Chem; 2007; 18(4):1338-43. PubMed ID: 17605463 [TBL] [Abstract][Full Text] [Related]
6. A nanoparticle for tumor targeted delivery of oligomers. Liu X; Wang Y; Hnatowich DJ Methods Mol Biol; 2011; 764():91-105. PubMed ID: 21748635 [TBL] [Abstract][Full Text] [Related]
7. Tumor delivery of antisense oligomer using trastuzumab within a streptavidin nanoparticle. Wang Y; Liu X; Chen L; Cheng D; Rusckowski M; Hnatowich DJ Eur J Nucl Med Mol Imaging; 2009 Dec; 36(12):1977-86. PubMed ID: 19572130 [TBL] [Abstract][Full Text] [Related]
8. In vivo delivery of antisense MORF oligomer by MORF/carrier streptavidin nanoparticles. Wang Y; Liu X; Nakamura K; Chen L; Rusckowski M; Hnatowich DJ Cancer Biother Radiopharm; 2009 Oct; 24(5):573-8. PubMed ID: 19877887 [TBL] [Abstract][Full Text] [Related]
9. Her2/neu small interfering RNA delivered in culture by a streptavidin nanoparticle. Liu X; Nakamura K; Cheng D; Peng C; Xiao N; Liu Y; Chen L; Rusckowski M; Hnatowich DJ Curr Drug Deliv; 2012 Jul; 9(4):431-6. PubMed ID: 22520071 [TBL] [Abstract][Full Text] [Related]
10. Intracellular routing in breast cancer cells of streptavidin-conjugated trastuzumab Fab fragments linked to biotinylated doxorubicin-functionalized metal chelating polymers. Liu P; Cai Z; Kang JW; Boyle AJ; Adams J; Lu Y; Ngo Ndjock Mbong G; Sidhu S; Reilly RM; Winnik MA Biomacromolecules; 2014 Mar; 15(3):715-25. PubMed ID: 24506198 [TBL] [Abstract][Full Text] [Related]
11. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. Costantini DL; Chan C; Cai Z; Vallis KA; Reilly RM J Nucl Med; 2007 Aug; 48(8):1357-68. PubMed ID: 17631548 [TBL] [Abstract][Full Text] [Related]
12. Construction of a novel chimera consisting of a chelator-containing Tat peptide conjugated to a morpholino antisense oligomer for technetium-99m labeling and accelerating cellular kinetics. Zhang YM; Tung CH; He J; Liu N; Yanachkov I; Liu G; Rusckowski M; Vanderheyden JL Nucl Med Biol; 2006 Feb; 33(2):263-9. PubMed ID: 16546682 [TBL] [Abstract][Full Text] [Related]
13. Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles. Cirstoiu-Hapca A; Bossy-Nobs L; Buchegger F; Gurny R; Delie F Int J Pharm; 2007 Mar; 331(2):190-6. PubMed ID: 17196347 [TBL] [Abstract][Full Text] [Related]
14. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose. Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198 [TBL] [Abstract][Full Text] [Related]
15. Multimodality nuclear and fluorescence tumor imaging in mice using a streptavidin nanoparticle. Liang M; Liu X; Cheng D; Liu G; Dou S; Wang Y; Rusckowski M; Hnatowich DJ Bioconjug Chem; 2010 Jul; 21(7):1385-8. PubMed ID: 20557066 [TBL] [Abstract][Full Text] [Related]
16. Three-step tumor imaging with biotinylated monoclonal antibody, streptavidin and 111In-DTPA-biotin. Nakamoto Y; Saga T; Sakahara H; Yao Z; Zhang M; Sato N; Zhao S; Nakada H; Yamashina I; Konishi J Nucl Med Biol; 1998 Feb; 25(2):95-9. PubMed ID: 9468022 [TBL] [Abstract][Full Text] [Related]
17. Controlled internalization of Her-2/ neu receptors by cross-linking for targeted delivery. Zhu W; Okollie B; Artemov D Cancer Biol Ther; 2007 Dec; 6(12):1960-6. PubMed ID: 18075296 [TBL] [Abstract][Full Text] [Related]
18. Effect of administration route and dose of streptavidin or biotin on the tumor uptake of radioactivity in intraperitoneal tumor with multistep targeting. Zhang M; Yao Z; Sakahara H; Saga T; Nakamoto Y; Sato N; Zhao S; Nakada H; Yamashina I; Konishi J Nucl Med Biol; 1998 Feb; 25(2):101-5. PubMed ID: 9468023 [TBL] [Abstract][Full Text] [Related]
19. 111In-labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1. Cornelissen B; Kersemans V; McLarty K; Tran L; Reilly RM Cancer Biother Radiopharm; 2009 Apr; 24(2):163-73. PubMed ID: 19409037 [TBL] [Abstract][Full Text] [Related]
20. Increased streptavidin uptake in tumors pretargeted with biotinylated antibody using a conjugate of streptavidin-fab fragment. Yao Z; Zhang M; Sakahara H; Saga T; Kobayashi H; Nakamoto Y; Toyama S; Konishi J Nucl Med Biol; 1998 Aug; 25(6):557-60. PubMed ID: 9751423 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]